Opendata, web and dolomites

EPIORGABOLISM SIGNED

Diabetic nephropathy modelling in hESC-derived 3D kidney organoids

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 EPIORGABOLISM project word cloud

Explore the words cloud of the EPIORGABOLISM project. It provides you a very rough idea of what is the project "EPIORGABOLISM" about.

impediments    hypothesize    organoids    model    expertise    epigenetic    dn    genetic    genes    therapies    oxidation    aberrant    disease    kidney    drugs    metabolism    structural    engineered    crispr    elucidate    date    physiological    human    stages    regeneration    progression    cas9    preclinical    discovery    occurring    therapy    status    epigenome    drug    differentiation    hesc    recapitulate    chemistry    acid    esrd    vitro    somatic    fatty    epithelial    ing    acting    dna    proximal    stop    encoding    evidences    diabetes    lack    validated    tissue    therapeutic    montserrat    stage    tubular    pathology    fibrosis    reprograming    alterations    regulators    links    metabolic    tool    signature    enhancers    gained    promoters    models    treatment    good    reprogramming    cell    dr    mainly    blood    nephropathy    promoted    architecture    diabetic    mimic    kptcs    background    serve    pressure    methylation    enzymes    embryonic    cells    functional    glycaemic    vivo    patients    stem    renal    molecular   

Project "EPIORGABOLISM" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA 

Organization address
address: CARRER BALDIRI REIXAC PLANTA 2A 10-12
city: BARCELONA
postcode: 8028
website: http://www.ibecbarcelona.eu

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Total cost 158˙121 €
 EC max contribution 158˙121 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2017
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2019
 Duration (year-month-day) from 2019-04-18   to  2021-08-14

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO INSTITUT DE BIOENGINYERIA DE CATALUNYA ES (BARCELONA) coordinator 158˙121.00

Map

 Project objective

Diabetic Nephropathy is the leading cause of end-stage renal disease (ESRD). To date, treatment of DN is mainly based on drugs acting on glycaemic and blood pressure control, as there is no validated therapy able to stop the progression towards renal failure. One of the main impediments for developing new therapies for DN has been the lack of a good preclinical model which can recapitulate important functional, structural, and molecular features of advanced human diabetic kidney disease. Here, we aim to develop a DN modelling using human Embryonic Stem Cell (hESC) derived kidney organoids which can recapitulate the in vivo architecture, functionality, and genetic signature of DN. Due to the increasing evidences that links aberrant DNA methylation with kidney fibrosis and metabolic reprograming in DN, we hypothesize that early DN progression is promoted by the metabolic alterations occurring in diabetic patients, resulting in the epigenetic reprogramming of kidney proximal tubular epithelial cells (KPTCs). Based in my background in the fields of metabolism and diabetes, together with the expertise of Dr. Montserrat in the field of somatic reprograming, DN and tissue regeneration/differentiation, this proposal seeks to:1) Elucidate the methylation status of the promoters/enhancers of genes encoding enzymes and regulators of fibrosis and fatty acid oxidation in proximal tubular cells obtained from diabetic patients at different stages of DN progression 2) Establish two in vitro models using hESC-derived kidney organoids; an engineered DN in vitro model, using CRISPR Cas9 to mimic the epigenome signature of DN patients and a physiological DN in vitro model which mimic the diabetic physiological chemistry. The information gained from this DN modelling will offer improved insight into disease pathology and progression. Moreover, it may also serve as a tool for drug discovery to identify therapeutic targets for DN.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "EPIORGABOLISM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "EPIORGABOLISM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

RipGEESE (2020)

Identifying the ripples of gene regulation evolution in the evolution of gene sequences to determine when animal nervous systems evolved

Read More  

MacMeninges (2019)

Control of Central Nervous Sytem inflammation by meningeal macrophages, and its impairment upon aging

Read More  

BIOplasma (2019)

Use flexible Tube Micro Plasma (FµTP) for Lipidomics

Read More